and anti-pan cytokeratin antibodies. GFP (+)/CD45 (À) cells were isolated and subjected to whole-genome amplification followed by polymerase chain reaction analysis of human papillomavirus (HPV) DNA. CTC were detected in 6 of 23 patients with cervical cancers (26.0%). Expression of CTC did not correlate with the stage of cancer or other clinicopathological factors. In 5 of the 6 CTC-positive cases, the same subtype of HPV DNA as that of the corresponding primary lesion was detected, indicating that the CTC originated from HPV-infected cancer cells. These CTC were all negative for cytokeratins. The CTC detected by our system were genetically confirmed. CTC derived from uterine cervical cancers had lost epithelial characteristics, indicating that epithelial marker-dependent systems do not have the capacity to detect these cells in cervical cancer patients.
| INTRODUCTION
Locally growing cancer cells need to intravasate to metastasize to distant organs. Difficulties have long been reported in identifying cancer cells in the bloodstream. 1 The clinical relevance of CTC as a prognostic or surrogate marker of treatment response has already been established for several cancer types, such as breast, colorectal, and prostate cancer. [2] [3] [4] We also previously showed the efficacy of CTC in gynecological cancers as a surrogate marker of treatment response. 5 The most commonly used CTC detection method is CellSearch â , which mainly relies on epithelial markers, such as the EpCAM and cytokeratins. 2, 6 The importance of this system is clear;
however, the expression of epithelial markers decreases during epithelial-to-mesenchymal transition, which may be associated with cancer progression and intravasation. 7 A previous study identified CTC with both epithelial and mesenchymal characteristics in patients with breast cancer, suggesting that epithelial characteristics are not essential for CTC. 8 There are several approaches for the isolation of CTC independent of epithelial markers, such as a method that assesses the size of cells 9 and a method based on dielectrophoresis. 10 However, a gold standard has not yet been established.
Immortality is one of the crucial characteristics of malignant cells.
Telomerase elongates chromosomal ends that shorten with every cell division, resulting in cell immortality. 11 The expression of telomerase is strictly controlled in normal cells 12 ; therefore, telomerase activity has potential as a marker of cancer cells. hTERT is the catalytic subunit of telomerase. 13, 14 The expression of hTERT has been identified as a determinant of telomerase activity and is transcriptionally regulated by its promoter. 15, 16 Telomerase-specific replication-selective adenoviruses have been constructed from adenovirus vectors by inserting the hTERT promoter upstream of E1A and E1B genes, thereby restricting their proliferation to telomerase-active cells only.
These adenoviruses have been applied to cancer virotherapy and visualization of cancer cells both in vitro and in vivo. [17] [18] [19] The GFPexpressing type of this virus (OBP-401) has been used to detect CTC in patients with various cancers. 5, 20, 21 CTC have been isolated and analyzed in patients with colorectal cancer using OBP-401. 22 However, the use of OBP-401 to detect CTC has some limitations.
It cannot infect CAR-negative cells because it is based on adenovirus serotype 5, and false-positive GFP signals caused by telomerasepositive blood cells may affect examinations and clinical decisions.
OBP-1101, a modified adenoviral vector, was recently developed. 23 In OBP-1101, adenovirus 5 fibers were exchanged for type 35 fibers, which bind to CD46, to infect CAR-negative cells, and complementary sequences of the blood cell-specific microRNA miR142-3p were inserted into the 3 0 -UTR of E1 and GFP genes to prevent false-positive signals in blood cells ( Figure 1A ).
In the present study, we focused on uterine cervical cancers because HPV genes are integrated into most cancer lesions and, thus, they have potential as good indicators of CTC. We applied the newly developed OBP-1101 to detect CTC in patients with cervical cancers to verify its efficacy and accuracy. CTC were immunocytologically characterized as to whether they expressed cytokeratins as epithelial markers. The origin of CTC was confirmed using PCR amplification of HPV genes. Louis, MO, USA), 100 lg/mL streptomycin, and 100 IU/mL penicillin.
| MATERIALS AND METHODS

| Patients
| Quantitative real-time RT-PCR analysis
Total RNA was extracted from frozen cervical cancer tissues using RNeasy Mini Kit (Qiagen, Venlo, Netherlands). cDNA was synthesized from total RNA using QuantiTect Reverse Transcription Kit (Qiagen). cDNA from 25 ng RNA was applied for real-time PCR assay using ABI PRISM 7700 Sequence Detection System (Thermo Fisher Scientific, Waltham, MA, USA). Expressions of hTERT and GAPDH mRNA were quantified by Taqman Gene Expression Assays Hs00972650_m1 and Hs02758991_g1 respectively (Thermo Fisher Scientific). All assays were carried out in triplicate. Expression of hTERT was standardized by that of GAPDH in each sample.
| Viruses
Viruses were propagated in HeLa-S3 cells, purified by ion-exchange chromatography and several steps of filtration, and stored at À80°C. 
| Blood sample preparation
The schematic flow diagram is shown in Figure S1 . Blood samples (7.5 mL) were drawn into citrate-, phosphate-, and dextrose-containing 
| Immunohistochemistry
Immunohistochemical analyses were carried out using 10% formalinfixed and paraffin-embedded specimens of cervical cancers. Specimens were deparaffinized in xylene and graded alcohol solutions.
Epitope retrieval was subsequently carried out; sections were heated for 10 minutes at 90°C in Antigen Retrieval Citra Solution (Bio- 
| HPV gene detection and mutation analysis in cancer samples
Genomic DNA was extracted from frozen or 10% formalin-fixed and paraffin-embedded specimens of cervical cancers using Dexpat (Takara, Kusatsu, Japan). HPV genes of subtypes 16, 18, 31, 33, 35, 52 , and 58 were detected using the Takara PCR Human Papillomavirus Typing Set (Takara). PCR was carried out to amplify DNA fragments within the ORF of E6 and E7 using the consensus primers pU-1M and pU-2R. Sequences of PCR primers and PCR conditions are listed in Table S1 . The amplified products were analyzed using restriction enzyme AvaII digestion patterns for HPV typing or direct sequencing. 26 PIK3CA exons 9 and 20 and KRAS exons 1 and 2 were also PCR amplified, and direct sequencing was done using the dideoxy chain termination method with the BigDye-Terminator cycle sequencing kit (Perkin-Elmer, Waltham, MA, USA). After ethanol precipitation, samples were analyzed using the ABI PRISM 3100 genetic analyzer (Thermo Fisher Scientific).
| HPV gene detection from CTC
Genomic DNA was extracted and amplified from CTC using the GenomePlex â Single Cell Whole-Genome Amplification Kit (SigmaAldrich). DNA fragments within the ORF of E6 and E7 were then amplified using HPV-type-specific primers. Sequences of PCR primers and PCR conditions are listed in Table S1 . Direct sequencing of PCR products was carried out as described previously.
| Statistical analysis
Linear regression analysis was carried out to evaluate the spike-in model experiments. To assess the significance of differences in the number of CTC, the chi-squared test, Mann-Whitney U test, t test, or Fisher's exact probability test was carried out. Survival analysis was done using the Kaplan-Meier method. The log-rank test was used to statistically compare the curves. All analyses were carried out using Microsoft Excel 2013. P-value < .05 was considered to indicate statistical significance.
3 | RESULTS
| GFP expression in OBP-1101-infected uterine cervical cancer cell lines in vitro and in spike-in models
We first evaluated the expression of GFP in the uterine cervical cancer cell lines HeLa, SiHa, and C33A using OBP-1101 ( Figure 1A ). In GFP (+) cells, the expressions of PKH26 and CD45 were completely independent of each other. We also carried out the same experiments using NSCLC cell line H1703 and synovial sarcoma cell line SYO-1 as a model of cytokeratin-negative mesenchymal tumor cells. 25, 27 The detection rate was 16% for H1703 and 27% for SYO-1, which was lower than that of cervical cancer cell lines (data not shown).
| Detection of CTC in patients with cervical cancer using OBP-1101
We Table 2) . The relationship between the existence of CTC and patient prognosis was evaluated using the Kaplan-Meier method ( Figure S2 ). There was no significant correlation between CTC and overall survival or progressionfree survival.
| Evaluation of epithelial cell markers in CTC and primary lesions
Immunocytological expression of epithelial markers, such as cytoker- 
| Evaluation of hTERT mRNA expression in primary lesions
Because the OBP-1101 system relies on hTERT promoter activity in cancer cells, we examined the levels of hTERT mRNA expression in primary lesions in 13 patients (3 CTC-positive and 10 CTC-negative) whose frozen tissues were available for quantitative RT-PCR. In 12 out of 13 patients, hTERT mRNA were detectable, and the only hTERT mRNA undetectable case was CTC-negative. There was no significant difference in hTERT expression between CTC-positive and -negative patients (Figure 3 ).
| Detection of HPV genes in CTC
We confirmed the presence of HPV genes in the primary lesions of CTC-positive patients. In 5 of 6 patients, HPV genes were amplified using consensus primers for the HPV subtypes 16, 18, 31, 33, 35, 52, and 58. The subtype of HPV was identified by the pattern of restriction enzyme AvaII digestion and direct sequencing of PCR products ( Figure S3A ). HPV types 16 and 33 DNA were detected in 4 patients and 1 patient, respectively (Table 1 ). In the remaining patient, the DNA of HPV type 16 had already been identified using the AMPLICORE â human papilloma virus test (Roche, Basel, Switzerland) in the initial diagnosis. We further investigated tumor-specific mutations in primary lesions. Because these mutation "hot spots"
were previously reported, PIK3CA exons 9 and 20 and KRAS exons 1 and 2 were also PCR amplified and directly sequenced. No mutations were found in the 5 patients whose genomic DNA from the primary lesion was available.
We then examined the presence of HPV genes in isolated CTC.
We carried out HPV-type-specific PCR of the E6/E7 region after whole-genome amplification ( Figure S3B ). The DNA sequences of PCR products were confirmed by direct sequencing. Identical types of HPV genes in the original lesions and CTC were successfully detected in 5 of 6 patients. However, we failed to detect the HPV gene in 1 patient whose CTC sample had been contaminated with 14 WBC (patient no. 4 in Table 1 ).
The existence of HPV genes in GFP (+)/CD45 (+) false-positive cells isolated from healthy volunteers was also examined. The cells were treated in the same way as CTC, but the HPV gene was not amplified in any sample (data not shown).
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| DISCUSSION
In the present study, we analyzed CTC in patients with cervical cancers using a telomerase-specific replication-selective adenovirus vec- 
28-32
We analyzed mutations in PIK3CA exons 9 and 20 and KRAS exons 1 and 2 in 5 patients whose genomic DNA from the primary lesion was available; however, no mutations were found. The rate of PIK3CA mutations in cervical cancer samples from Chinese individuals has been reported to be 12.3%, which is lower than the rate in other reports, suggesting that the ratio of PIK3CA mutations in cervical cancer is lower in Asia. [28] [29] [30] [31] [32] [33] This may affect the present data.
Owing to the relatively low ratio of somatic mutations, it appears problematic to prove that mutations are identical in primary lesions and CTC in cervical cancer.
HPV infection is associated with carcinogenesis in cervical cancer
and is detectable in more than 95% of cervical cancer cases. 34 We consequently adopted HPV genes as markers of cancer cells to evaluate the authenticity of CTC isolated in the present study. Several reports have carried out PCR amplification of HPV DNA or mRNA from peripheral blood cells to detect CTC in cervical cancer. [35] [36] [37] [38] [39] In older studies, PBMC fractions were directly subjected to analyses. [35] [36] [37] Existence of HPV DNA was associated with overall survival or poor prognosis in these studies. In a relatively recent report, PBMC fractions enriched with anti-EpCAM antibody were used for HPV RT-PCR. 38 Out of a total of 13 cervical cancer patients, 3 were positive for HPV mRNA (23%). In another study, digital RT-PCR analysis was carried out for HPV genes to estimate the presence of CTC.
39
Of 10 cervical cancer patients, 3 were positive.
In contrast, the existence of episomal HPV in PBMC of healthy donors has been reported. 40 The characteristics of HPV-positive cells in peripheral blood was analyzed in HPV16-infected males, which
showed that these cells were CD45 (+) and CD20 (+) or CD56 (+), likely phenotypes of B cells and NK cells, respectively. 41 The Table 1 ).
Our CTC collection system is automated, and the procedure is simple and easy to manipulate, but it was sometimes difficult to sepa- Because the CTC detection system using OBP-1101 depends on hTERT promoter activity, we examined hTERT mRNA expression in original lesions both in CTC-positive and -negative patients.
Except one CTC-negative patient, all samples expressed hTERT mRNA, but the levels of hTERT mRNA expression were not significantly different in CTC-positive and -negative patients, suggesting that the level of hTERT expression is not a simple determinant of CTC detection. One possible explanation of this result is that hTERT upregulation occurs at a single cell level, associating with intravasation of tumor cells as it is reported that hTERT promotes epithelial-mesenchymal transition and invasion of cancer cells. 43, 44 Other factors may also be involved in the detection of CTC, such as viral infectivity to CTC. We confirmed that OBP-1101 infection did not affect cytokeratin expression in vitro. We also examined a blood spike-in model using H1703, a cytokeratin-negative mesenchymal transformed NSCLC cell line, and SYO-1, a synovial sarcoma cell line. The detection ratios were lower than that of cervical cancer cell lines. It may be a reflection of lower infectivity of virus indicated in in vitro experiments shown in former reports. 24, 45 However, this result suggests that OBP-1101 does not preferentially detect cytokeratin-negative mesenchymal type cells. In relation to this result, both epithelial and mesenchymal-like CTC were detected in a recent study on CTC in NSCLC patients using OBP-1101. 45 These results indicate that Several studies on CTC in cervical cancer have been carried out, including HPV-PCR-based studies (as discussed earlier) and other such studies. 46, 47 However, these studies were relatively small. Some of them indicated a prognostic value or association with clinical findings; however, we did not find such associations in our data. There has been a relatively large-scale study of DTC in bone marrow. The number of CTC detected in this study was relatively small (2.5 AE 1.3 cells/7.5 mL). However, it is consistent with recent studies using OBP-1101 in NSCLC (2.1 AE 1.8 and 2.3 AE 0.3). 23, 45 To improve the sensitivity, increasing viral dose or extending reaction time may be useful. Further studies are necessary to determine optimal conditions for CTC detection.
In the present study, CTC were detected in 3 of 11 cases with stage IB disease who had no recurrence for at least 2 years, suggesting that existence of CTC is not directly associated with the presence of distal metastasis. Further characterization of CTC is necessary to distinguish CTC that associate with metastasis from those that do not.
There are limitations in the present study. First, because of the small number of patients, we could not reach a definitive result of clinical relevance of CTC in cervical cancer and could not carry out enough genetic analyses of CTC. Second, we did not examine the expression of mesenchymal markers in CTC, such as vimentin, which are necessary to show the character of CTC more clearly.
In conclusion, this is the first study that genetically confirmed 
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